Zobrazeno 1 - 10
of 81
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
John C. Byrd, Deborah M. Stephens
Publikováno v:
Blood
Bruton tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape for patients with B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma
Autor:
Laurence Kraus-Berthier, Lucie Laplane, Véronique Saada, Céline Berthon, Maria E. Figueroa, Bouchra Badaoui, Margaux Sevin, Franck Debeurme, Eric Padron, Thorsten Braun, Qin Yang, Nathalie Droin, Raphael Itzykson, Guido Kroemer, Dorothée Selimoglu-Buet, Eric Solary, Oliver Kepp, Margot Morabito, Alix Derreal, Hannah Newman, Sylvain Thepot, Gabriel Etienne, Miguel Torres-Martin, Sébastien Banquet, Severine Badel, Orianne Wagner-Ballon, Pierre Fenaux
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in
Autor:
Isabelle S. Csete, Ross L. Levine, Qi Gao, Alexander Chan, Andriy Derkach, Maximilian Stahl, Sheng F. Cai, Jinjuan Yao, Tanmay Mishra, Richard Koche, Sophia Yanis, Martin S. Tallman, Aaron D Goldberg, Michael R. Waarts, Raajit K. Rampal, Ahmet Dogan, Robert L. Bowman, Minal Patel, Ying Liu, Wenbin Xiao, Mikhail Roshal, Maria E. Arcila, Jeeyeon Baik, Nicole L. DelGaudio, Christopher Famulare, Yanming Zhang
Publikováno v:
Blood
Plasmacytoid dendritic cells (pDCs) are the principal natural type I interferon–producing dendritic cells. Neoplastic expansion of pDCs and pDC precursors leads to blastic plasmacytoid dendritic cell neoplasm (BPDCN), and clonal expansion of mature
Autor:
Satoshi Yamashita, Naoko Hattori, Yuki Kurahashi, Toshikazu Ushijima, Naoko Sueoka-Aragane, Tatsuro Watanabe, Akemi Sato, Kensuke Kojima, Hideaki Nakamura, Atsushi Kawaguchi, Shinya Kimura, Eisaburo Sueoka, Nao Yoshida, Kazuharu Kamachi, Seiji Okada, Hiroshi Ureshino, Yuki Fukuda-Kurahashi
Publikováno v:
Blood. 136:871-884
Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+ T cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1–infected individuals are asymptomatic, and only 3% to 5% of carriers develop ATL.
Autor:
Ming Hou, Fangmiao Jing, Yang Liu, Tao Sun, Yajing Zhao, Hong-yu Zhao, Yu Hou, Hai Zhou, Lizhen Li, Ya-hui Ma, Panpan Han, Xinguang Liu, Ping Li, Jun Peng, Daqi Li
Publikováno v:
Blood. 133:730-742
Increased macrophage phagocytosis of antibody-coated platelets, as well as decreased numbers and/or impaired function of CD4+CD25+Foxp3+ regulatory T (Treg) cells, has been shown to participate in the pathogenesis of immune thrombocytopenia (ITP). Lo
Autor:
Ester B. M. Remmerswaal, Arnon P. Kater, Iris de Weerdt, Ineke J. M. ten Berge, Tom Hofland, Perry D. Moerland, Nora Liu, Laura M. Faber, Roeland Lameris, Mark-David Levin, Mario van der Stelt, Sanne Endstra, Sanne H. Tonino, Hans van Vliet, Aldo Jongejan, Renée C.G. de Bruin, Eric Eldering, Tanja D. de Gruijl
Publikováno v:
Blood
de Weerdt, I, Hofland, T, Lameris, R, Endstra, S, Jongejan, A, Moerland, P D, de Bruin, R C G, Remmerswaal, E B M, Ten Berge, I J M, Liu, N, van der Stelt, M, Faber, L M, Levin, M-D, Eldering, E, Tonino, S H, de Gruijl, T D, van der Vliet, H J & Kater, A P 2018, ' Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib ', Blood, vol. 132, no. 21, pp. 2260-2272 . https://doi.org/10.1182/blood-2017-12-822569
Blood, 132(21), 2260-2272
Blood, 132(21), 2260-2272. American Society of Hematology
de Weerdt, I, Hofland, T, Lameris, R, Endstra, S, Jongejan, A, Moerland, P D, de Bruin, R C G, Remmerswaal, E B M, Ten Berge, I J M, Liu, N, van der Stelt, M, Faber, L M, Levin, M-D, Eldering, E, Tonino, S H, de Gruijl, T D, van der Vliet, H J & Kater, A P 2018, ' Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib ', Blood, vol. 132, no. 21, pp. 2260-2272 . https://doi.org/10.1182/blood-2017-12-822569
Blood, 132(21), 2260-2272
Blood, 132(21), 2260-2272. American Society of Hematology
The efficacy of autologous (αβ) T-cell–based treatment strategies in chronic lymphocytic leukemia (CLL) has been modest. The Vγ9Vδ2-T cell subset consists of cytotoxic T lymphocytes with potent antilymphoma activity via a major histocompatibili
Autor:
Tomomitsu Miyagaki, Tomonori Oka, Rina Nakajima, Shinichi Sato, Hiraku Suga, Hiroaki Kamijo, Makoto Sugaya, Naomi Shishido-Takahashi
Publikováno v:
Blood. 132:1922-1935
CD137 and its ligand, CD137L, are expressed on activated T cells and antigen-presenting cells, respectively. Recent studies have shown that CD137L and CD137 are aberrantly expressed by tumor cells, especially in some hematopoietic malignancies, and i
Autor:
James O. Lindsay, Maria Calaminci, Matt Mee, John G. Gribben, Jamie D. Cavenagh, James Aries, Jennifer A. Ball, Andrew J. Stagg, Sarah Charrot, Andrew Clear, Jeff K. Davies, Caroline Besley
Publikováno v:
Blood. 137(5)
Gastrointestinal (GI) graft-versus-host disease (GVHD) is a major barrier in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The metabolite retinoic acid (RA) potentiates GI-GVHD in mice via alloreactive T cells expressing the RA rece
Publikováno v:
Blood. 134(11)
Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle ar